Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States
Author:
Affiliation:
1. Brigham and Women's Hospital
2. Brigham and Women's Hospital and Harvard Medical School Boston MA
Publisher
Wiley
Subject
Immunology,Rheumatology,Immunology and Allergy
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41201
Reference3 articles.
1. The US Biosimilar Market: Stunted Growth and Possible Reforms
2. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
3. Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis;Arthritis Care & Research;2023-03-04
2. Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions;BMC Rheumatology;2022-12-23
3. Patient Out‐of‐Pocket Costs Following the Availability of Biosimilar Versions of Infliximab;Clinical Pharmacology & Therapeutics;2022-11
4. Moving forward: Implementing health psychology research to improve patient acceptance of biosimilars;Research in Social and Administrative Pharmacy;2022-10
5. Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases;Seminars in Arthritis and Rheumatism;2022-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3